Resveratrol does not benefit patients with nonalcoholic fatty liver disease

Veronique S Chachay, Graeme A Macdonald, Jennifer H Martin, Jonathan P Whitehead, Trisha M O'Moore--Sullivan, Paul Lee, Michael Franklin, Kerenaftali Klein, Paul J Taylor, Maree Ferguson, Jeff Coombes, Gethin Thomas, Gary J. Cowin, Carl Kirkpatrick, Johannes B Prins, Ingrid Hickman

    Research output: Contribution to journalArticlepeer-review

    249 Citations (Scopus)


    Nonalcoholic fatty liver disease (NAFLD), characterized by accumulation of hepatic triglycerides (steatosis), is associated with abdominal obesity, insulin resistance, and inflammation. Although weight loss via calorie restriction reduces features of NAFLD, there is no pharmacologic therapy. Resveratrol is a polyphenol that prevents high-energy diet-induced steatosis and insulin resistance in animals by up-regulating pathways that regulate energy metabolism. We performed a placebo-controlled trial to assess the effects of resveratrol in patients with NAFLD.
    Original languageEnglish
    Pages (from-to)2092-2103.e6
    Number of pages18
    JournalClinical Gastroenterology and Hepatology
    Issue number12
    Publication statusPublished - 2014


    Dive into the research topics of 'Resveratrol does not benefit patients with nonalcoholic fatty liver disease'. Together they form a unique fingerprint.

    Cite this